EZH2 and neoplasm: A study on the expression of this protein in NSCLC found that patients who had high EZH2 expression in tumor cells had a poorer prognosis than patients who had low EZH2 expression in tumor cells for all pathologic stages of NSCLC (P = 0.001), and that high EZH2 expression was correlated significantly with nonadenocarcinoma histology (P = 0.001) [95] (Table 3).